Amgen has reported positive phase 3 results ... for additional indications on Soliris' label like generalised myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).

Amgen is preparing to file a third indication for Uplizna, as a twice-yearly therapy for generalised myasthenia gravis, following new phase 3 data.

Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.

Rozanolixizumab is a high-affinity humanized immunoglobulin G4 monoclonal antibody and Fc receptor blocker approved to treat ...

Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 19 unusual trades. Delving into the details, we found 26% of traders were ...

Johnson & Johnson presented new data on its investigational treatment, nipocalimab, at the 2025 American Academy of Neurology ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The company’s shares closed yesterday at $314.38.

highlighting the Company's innovative autoantibody disease research and the potential of nipocalimab to provide long-term sustained disease control in the treatment of generalized myasthenia ...

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for Immutep Global Phase III with efti will enrol approximately 756 patients at more than ...